Top

Published in:

01-07-2017 | Original Article

The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy

Authors: Peng Sun, Cong Xue, Li-Ren Li, Cui Shao, Xin An, Ried Thomas, Wei Yang, Ying-Fei Deng, Wen-Qi Jiang, Yan-Xia Shi

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2017

Abstract

Purpose

The renal safety of cisplatin-based chemotherapy has not been investigated in patients with urothelial carcinoma of the upper urinary tract (UUT-UC) who retain a solitary kidney after nephroureterectomy. This study aimed to assess and compare the renal safety and efficacy of gemcitabine–cisplatin (GP) and gemcitabine–carboplatin (GC) in these patients.

Methods

The medical records of patients diagnosed with urothelial carcinoma at the Sun Yat-Sen University Cancer Center between January 2005 and December 2015 were retrospectively reviewed. The creatinine clearance (CrCl) and estimated glomerular filtration rate (eGFR) were used to assess renal function and were calculated using different formulas.

Results

A total of 71 patients were enrolled in this study; 48 patients were on GP, and 23 were on GC. The renal function indicators (CrCl and eGFR) were all significantly lower after GP chemotherapy than at baseline, a phenomenon that was not observed in the GC group. Severe nephrotoxicities (SNTs) were reported in 12 patients on GP (25%) and zero on GC. SNT risk factors included a more than 20% decrease in eGFR after one GP cycle and the presence of diabetes (all p < 0.05). Among patients treated with first-line palliative chemotherapy (n = 32), GC (n = 13) patients had an ORR of 46.2%, which was not significantly different from GP patients (36.8%, n = 19), whereas GC patients tended to have a shorter OS than GP patients (9.2 vs. 29 months, p = 0.200).

Conclusions

Our results confirm that GP has an adverse impact on the renal function of patients with UUT-UC who retain a solitary kidney, but it can be safely administered to the majority of these patients without inducing SNT. In specific patients, GC is an alternative to GP that has comparable efficacy and favourable renal toxicity.

Ho GY, Woodward N, Coward JI (2016) Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 102:37–46CrossRefPubMed

Necchi A, Pond GR, Raggi D et al (2017) Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer 15:23–30.e2CrossRefPubMed

Sumiyoshi T, Matsumoto K, Utsunomiya N, Segawa T, Muguruma K, Kawakita M (2013) Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer. Hinyokika Kiyo 59(1):1–6PubMed

Vassilakopoulou M, de la Motte Rouge T, Colin P et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 117(24):5500–5508CrossRefPubMed

Rai BP, Shelley M, Coles B, Somani B, Nabi G (2012) Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. BJU Int 110:1426–1435CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30CrossRefPubMed

Painter DJ, Timoney AG, Denton K, Alken P, Keeley FX (2007) The modern management of upper urinary tract urothelial cancer: tumour diagnosis, grading and staging. BJU Int 99:973–977CrossRefPubMed

Hsieh MC, Chiang PH, Rau KM, Chen YY, Su YL, Huang CH (2015) The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy. Urol Oncol 33(11):495.e9–495.e14CrossRef

Kikuchi E, Miyazaki J, Yuge K et al (2016) Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience. Jpn J Clin Oncol 46(2):163–169PubMed

10.

Kim TS, Oh JH, Rhew HY (2013) The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. J Cancer 4(8):686–690CrossRefPubMedPubMedCentral

11.

Audenet F, Yates DR, Cussenot O, Rouprêt M (2013) The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol 31(4):407–413CrossRefPubMed

12.

Fujita K, Inamoto T, Yamamoto Y et al (2015) Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: a multi-institutional, retrospective study. Int J Urol 22(11):1006–1012CrossRefPubMed

13.

Huang YC, Chen MF, Shi CS et al (2015) The efficacy of postoperative adjuvant chemotherapy for patients with pT3N0M0 upper tract urothelial carcinoma. J Urol 194(2):323–329CrossRefPubMed

14.

Rouprêt M, Babjuk M, Compérat E et al (2015) European Association of Urology Guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 68:868–879CrossRefPubMed

15.

O’Donnell PH, Stadler WM (2009) The role of chemotherapy in upper tract urothelial carcinoma. Adv Urol 2009:419028PubMedCentral

16.

Xiong G, Chen X, Li X et al (2014) Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. J Formos Med Assoc 113(8):521–526CrossRefPubMed

17.

Lane BR, Smith AK, Larson BT et al (2010) Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 116(12):2967–2973CrossRefPubMed

18.

Cho KS, Joung JY, Seo HK et al (2011) Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract. Cancer Chemother Pharmacol 67(4):769–774CrossRefPubMed

19.

Pavelka M, Lucas MF, Russo N (2007) On the hydrolysis mechanism of the second-generation anticancer drug carboplatin. Chemistry 13:10108–10116CrossRefPubMed

20.

Dogliotti L, Cartenì G, Siena S et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52(1):134–141CrossRefPubMed

21.

De Santis M, Bellmunt J, Mead G et al (2009) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J Clin Oncol 27(33):5634–5639CrossRefPubMedPubMedCentral

22.

Faluyi OO, Masinghe SP, Hayward RL, Clive S (2012) Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in oncology patients with renal impairment. Med Oncol 29(2):755–760CrossRefPubMed

23.

Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612CrossRefPubMedPubMedCentral

24.

Yoshida K, Yamazaki H, Nakamara S et al (2014) Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer. Anticancer Res 34(4):2015–2018PubMed

25.

Aras M, Erdil TY, Dane F et al (2016) Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. Nucl Med Commun 37(1):9–15PubMed

26.

Moore MJ, Winquist EW, Murray N et al (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17(9):2876–2881CrossRefPubMed

27.

der Maase HV, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21):4602–4608CrossRefPubMed

28.

Roberts JT, der Maase HV, Sengeløv L et al (2006) Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 17(Suppl 5):v118–v122CrossRefPubMed

29.

Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66(3):529–541CrossRefPubMed

30.

Yafi FA, Tanguay S, Rendon R et al (2014) Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urol Oncol 32(1):31.e17-24PubMed

31.

Dash A, Galsky MD, Vickers AJ et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107(3):506–513CrossRefPubMed

32.

Kaag MG, O’Malley RL, O’Malley P et al (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58(4):581–587CrossRefPubMedPubMedCentral

33.

Shao IH, Lin YH, Hou CP et al (2014) Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. Drug Des Dev Ther 8:1985–1990

34.

Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2(11):2490–2518CrossRef

35.

Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994–1007CrossRefPubMed

36.

Kobayashi S, Ueno M, Ohkawa S, Irie K, Goda Y, Morimoto M (2014) Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary tract cancer. Oncology 87(1):30–39CrossRefPubMed

37.

Máthé C, Bohács A, Duffek L et al (2011) Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J 37:888–894CrossRefPubMed

38.

Hosohata K, Washino S, Kubo T, Natsui S, Fujisaki A, Kurokawa S, Ando H, Fujimura A, Morita T (2016) Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma. Toxicology 359–360:71–75CrossRefPubMed

39.

Nogué-Aliguer M, Carles J, Arrivi A et al (2003) Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97(9):2180–2186CrossRefPubMed

40.

Park JH, Lee SW, Kim HS et al (2013) Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 71(4):1033–1039CrossRefPubMed

41.

Daw NC, Gregornik D, Rodman J et al (2009) Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour. Eur J Cancer 45(1):99–106CrossRefPubMed

42.

Beumer JH, Ding F, Tawbi H et al (2016) Effect of renal dysfunction on toxicity in three decades of cancer therapy evaluation program-sponsored single-agent phase I studies. J Clin Oncol 34(2):110–116CrossRefPubMed

43.

Funakoshi Y, Fujiwara Y, Kiyota N et al (2016) Validity of new methods to evaluate renal function in cancer patients treated with cisplatin. Cancer Chemother Pharmacol 77(2):281–288CrossRefPubMedPubMedCentral

44.

Raj GV, Iasonos A, Herr H, Donat SM (2006) Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 24(19):3095–3100CrossRefPubMed

Title: The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy
Authors: Peng Sun
Cong Xue
Li-Ren Li
Cui Shao
Xin An
Ried Thomas
Wei Yang
Ying-Fei Deng
Wen-Qi Jiang
Yan-Xia Shi
Publication date: 01-07-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3316-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Efficacy and safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for high-risk head and neck cancer patients in Japan

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient

βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel

UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis

Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer